FDA Prioritizes New Technologies, Nano Included, In Regulatory Science Plan
This article was originally published in The Rose Sheet
Executive Summary
FDA plans to invest in eight priority areas for regulatory science, with the goal of improving its handle on emerging technologies such as nanotechnology, elevating the quality of clinical trial data and developing better tools for reviewing manufacturing systems, according to a strategic plan.